Cytek BiosciencesCTKB +0.11%71 Current Ratio is 4.69 as of Mar. 2026, which is 36% below its 10-year median of 7.33. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 75.29% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cytek Biosciences's current ratio for the quarter that ended in Mar. 2026 was 4.69.
Cytek Biosciences has a current ratio of 4.69. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cytek Biosciences's Current Ratio or its related term are showing as below:
CTKB'
s Current Ratio Range Over the Past 10 Years
Min: 3.22 Med: 7.33 Max: 14.65
Current: 4.69
During the past 7 years, Cytek Biosciences's highest Current Ratio was 14.65. The lowest was 3.22. And the median was 7.33.
CTKB's Current Ratio is ranked better than 75.29% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs CTKB: 4.69
Cytek Biosciences (NAS:CTKB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cytek Biosciences Current Ratio Related Terms
Cytek Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs BBNX, TCMD, NPCE: Current Ratio Comparison
For the Medical Devices subindustry, Cytek Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Current Ratio of 4.69 as of Mar. 2026. This is 36% below median its historical median of 7.33. Over the past decade, Cytek Biosciences' Current Ratio has ranged from 3.22 to 14.65. According to the industry distribution chart, Cytek Biosciences ranks #211 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 24.7%.
Is Cytek Biosciences' Current Ratio too high?
Cytek Biosciences' current Current Ratio of 4.69 is 36% below median its 10-year median of 7.33. Over the past 10 years, this metric has ranged from a low of 3.22 to a high of 14.65. The Medical Devices & Instruments industry median Current Ratio is 2.49. Cytek Biosciences' value of 4.69 is 88.7% above this industry median. Based on the distribution chart, Cytek Biosciences ranks #211 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Current Ratio compare to BBNX and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #211 out of 854 companies for Current Ratio. This places Cytek Biosciences in the top 25% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. Cytek Biosciences' value of 4.69 is 88.7% above this benchmark. Historically, Cytek Biosciences' own Current Ratio has ranged from 3.22 to 14.65 over the past decade. While the company's 10-year median is 7.33 vs. the industry median of 2.49, Cytek Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Current Ratio of 4.69 is 88.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Current Ratio is 4.69, which is 36% below median its own 10-year median of 7.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.46 — trading 23.4% below its estimated fair value. The current Current Ratio is 4.69, which is 36% below median its 10-year median of 7.33 and 88.7% above the Medical Devices & Instruments industry median of 2.49. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Current Ratio is 4.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.46 is trading 23.4% below its estimated GF Value™ of $5.82.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Current Ratio: 4.69 (36% below median its 10-year median of 7.33)
GF Value™: $5.82 vs. price of $4.46 (23.4% below fair value)
Industry Position: 88.7% above the Medical Devices & Instruments median (#211 of 854)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
